Exploring the impact of wearing-off phenomenon in ocrelizumab-treated multiple sclerosis patients: Insights from a comprehensive study

Basit Öğe Kaydı
dc.authoridAydin Turkoglu, Sule/0000-0001-8616-832X
dc.authoridTUNC, Abdulkadir/0000-0002-9747-5285
dc.contributor.authorSeferoglu, Meral
dc.contributor.authorTunc, Abdulkadir
dc.contributor.authorSivaci, Ali Ozhan
dc.contributor.authorUzuner, Gulnur Tekgol
dc.contributor.authorMungan, Semra
dc.contributor.authorInanc, Yilmaz
dc.contributor.authorYetkin, M. Fatih
dc.date.accessioned2025-01-27T21:13:09Z
dc.date.available2025-01-27T21:13:09Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: Ocrelizumab (OCR) effectively modifies the disease course in multiple sclerosis (MS) patients but may cause a preinfusion wearing-off phenomenon (WoP). This study explored the prevalence, timing, and severity of this phenomenon in MS patients using the OCR, as well as the associated symptoms and treatment satisfaction. Methods: We conducted a prospective multicenter study across 11 MS centers involving MS patients aged 18-70 years who had received at least two OCR doses. The study employed a questionnaire addressing demographic, clinical, and radiological data; symptom progression; and treatment satisfaction. Results: Of the 409 patients included in the study, 406 participated. A significant portion experienced varying degrees of WoP: 39.2% sometimes, 25.9% usually, and 14.3% always, with 55.9% noting symptom onset over four weeks prior to their next dose. Common symptoms included fatigue, walking difficulties, and pain. Subgroup analysis of 334 patients revealed that 78.1% of patients experienced these effects, which correlated with shorter disease durations, a longer delay between the two doses before the last dose, and a greater rate of relapse (P>0.05). Conclusion: The WoP of the OCR is prevalent and significant among MS patients and is influenced by the dosing interval, disease duration, and relapse rate. These insights underscore the need for personalized treatment schedules and more research into factors affecting MS management.
dc.identifier.doi10.1016/j.msard.2024.105939
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid39423725
dc.identifier.scopus2-s2.0-85206439867
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.msard.2024.105939
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28309
dc.identifier.volume92
dc.identifier.wosWOS:001340407600001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectMultiple sclerosis
dc.subjectOcrelizumab
dc.subjectDrug-related side effects and adverse reactions
dc.subjectPatient satisfaction
dc.subjectPatient reported outcome
dc.titleExploring the impact of wearing-off phenomenon in ocrelizumab-treated multiple sclerosis patients: Insights from a comprehensive study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu